NYSE:IEXMachinery
How IDEX’s Upgraded 2026 Outlook and Health & Science Momentum Could Shape IDEX (IEX) Investors
Earlier in 2026, IDEX Corporation reported stronger-than-expected first-quarter results and lifted its full-year 2026 guidance, citing record orders and raising organic sales growth expectations to 3%–4% alongside an adjusted EPS range of US$8.35 to US$8.55.
A key insight from this update is the surge in demand within IDEX’s Health & Science Technologies segment, where AI infrastructure, semiconductor, medical, and defense-related markets are emerging as important growth engines.
We’ll now...